Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Iodixanol
Drug ID BADD_D01178
Description Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.
Indications and Usage Iodixanol is a contrast agent during coronary angiography.
Marketing Status approved
ATC Code V08AB09
DrugBank ID DB01249
KEGG ID D01474
MeSH ID C044834
PubChem ID 3724
TTD Drug ID D0Y4YG
NDC Product Code 71806-222; 65219-381; 0407-2223; 65219-383; 0407-2222; 57884-0029
UNII HW8W27HTXX
Synonyms iodixanol | Visipaque | Visipaque Unique Softpac | iodixanol-320 | contrast media 2-5410-3
Chemical Information
Molecular Formula C35H44I6N6O15
CAS Registry Number 92339-11-2
SMILES CC(=O)N(CC(CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)C)O)C2=C(C(= C(C(=C2I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood creatinine increased13.13.01.004--
Blood pressure fluctuation24.06.01.0020.007113%Not Available
Blood urea increased13.13.01.006--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Bradycardia02.03.02.0020.024897%Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchospasm22.03.01.004; 10.01.03.0120.046237%
Bundle branch block02.03.01.009--Not Available
Burning sensation17.02.06.001; 08.01.09.0290.017783%Not Available
Cardiac arrest02.03.04.0010.053350%
Cardiac failure02.05.01.001--
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.065443%Not Available
Cardiogenic shock02.05.01.003; 24.06.02.0060.017783%Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.017783%Not Available
Cerebrovascular disorder24.03.05.002; 17.08.02.002--Not Available
Cheilitis23.03.03.025; 07.05.01.0010.015649%
Chest discomfort08.01.08.019; 02.02.02.009; 22.12.02.0020.149381%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.056196%Not Available
Chills15.05.03.016; 08.01.09.0010.133020%
Choking22.12.03.003--Not Available
Choking sensation22.12.03.004; 19.01.02.0020.007113%Not Available
Circulatory collapse24.06.02.0010.017783%Not Available
Coagulopathy01.01.02.001--Not Available
Cold sweat23.02.03.002; 08.01.03.0240.042680%Not Available
Colour blindness acquired06.02.09.002--Not Available
Coma17.02.09.001--Not Available
Compartment syndrome24.04.05.006; 15.05.05.0050.010670%Not Available
Conduction disorder02.03.01.008--
Confusional state19.13.01.001; 17.02.03.005--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene